These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 20956959)
1. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder. Johansson JE; Remberger M; Lazarevic VLj; Hallböök H; Wahlin A; Kimby E; Juliusson G; Omar H; Hägglund H Bone Marrow Transplant; 2011 Jun; 46(6):870-5. PubMed ID: 20956959 [TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967 [TBL] [Abstract][Full Text] [Related]
3. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794 [TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
5. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI; Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879 [TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796 [TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502 [TBL] [Abstract][Full Text] [Related]
8. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043 [TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860 [TBL] [Abstract][Full Text] [Related]
16. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114 [TBL] [Abstract][Full Text] [Related]
17. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]
18. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Juvonen E; Aalto SM; Tarkkanen J; Volin L; Mattila PS; Knuutila S; Ruutu T; Hedman K Bone Marrow Transplant; 2003 Jul; 32(1):97-102. PubMed ID: 12815484 [TBL] [Abstract][Full Text] [Related]
19. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Shaw BE; Mufti GJ; Mackinnon S; Cavenagh JD; Pearce RM; Towlson KE; Apperley JF; Chakraverty R; Craddock CF; Kazmi MA; Littlewood TJ; Milligan DW; Pagliuca A; Thomson KJ; Marks DI; Russell NH Bone Marrow Transplant; 2008 Dec; 42(12):783-9. PubMed ID: 18724393 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Sureda A; Schmitz N Ann Hematol; 2003 Jan; 82(1):1-13. PubMed ID: 12574957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]